|Year : 2002 | Volume
| Issue : 2 | Page : 88-91
Efficacy of H, antihistamine, corticosteroids and cyclophosphamide in the treatment of chronic dermographic urticaria
Rajesh Kumar, Kaushal K Verma, JS Pasricha
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi
Source of Support: None, Conflict of Interest: None
H, antihistamines relieve urticaria by blocking the action of histamine on the target tissue, while demonstration of autoantibodies in the sera of a proportion of the patients having chronic idiopathic urticaria, use of immunosuppressive drugs for the treatment of these patients has acquired the greater rationality. We evaluated the role of corticosteroids and cyclophosphamide in the treatment of chronic dermographic urticaria. Twenty-five patients, 13 males and 12 females, between 18-53 years in age, having chronic dermographic urticaria were taken up for this study. The patients were divided into three groups. Group I patients (n=9) were treated with cetirizine hydrochloride 10 mg per day orally, group II patients (n=7) were treated with betamethasone 2 mg along with cyclophosphamide 50 mg along with cetirizine 10 mg per day for a total period of 4 weeks. The patients were evaluated every week to record the therapeutic response and side effects, and then followed up without treatment for a period of 6 months to look for recurrence of the urticaria, if any. Six patients in group I and all the patients in group II and group III had complete remission while the remaining patients in group I had partial relief. The side effects included drowsiness in 4 patients. All the patients in group II had weight gain, 4 patients had acne and 2 patients developed cushingoid features. Majority of the patients relapsed within 3 days after stopping the treatment. Supplementation of the treatment with oral corticosteroids or cyclophosphamide was more effective in controlling the symptoms as compared to cetirizine alone. But a four weeks supplementation was not adequate for preventing the relapses when the drugs were withdrawn.
Keywords: Dermographic urticaria, Corticosteroids, Cyclophosphamide
|How to cite this article:|
Kumar R, Verma KK, Pasricha J S. Efficacy of H, antihistamine, corticosteroids and cyclophosphamide in the treatment of chronic dermographic urticaria. Indian J Dermatol Venereol Leprol 2002;68:88-91
|How to cite this URL:|
Kumar R, Verma KK, Pasricha J S. Efficacy of H, antihistamine, corticosteroids and cyclophosphamide in the treatment of chronic dermographic urticaria. Indian J Dermatol Venereol Leprol [serial online] 2002 [cited 2020 Oct 22];68:88-91. Available from: https://www.ijdvl.com/text.asp?2002/68/2/88/12605
| Introduction|| |
It is interesting to realise that H1 antihistamines used for the treatment of urticaria merely block the receptors and do nothing to the mechanism responsible for urticaria. The urticaria is therefore likely to reappear when the antihistamines are withdrawn unless the cause has disappeared during this period. In patients having dermographic urticaria or the recently described auto-immune urticaria,,, the urticaria generally recurs whenever the antihistamines are withdrawn, leading to the consequent frustration in the patient. Sometimes in addition, the Hi antihistamines are unable to control the disease in a patient, therefore immunosuppressive drugs like methotrexate, cyclosporine and corticosteroids have been used for its treatment.,, We have compared the therapeutic efficacy of a H1 antihistamine used alone and in combination with oral corticosteroids or cyclophosphamide.
| Materials and Methods|| |
Twenty-five patients, 13 males and 12 females, between 18-53 years in age (mean age 31.12 years) having dermographic urticaria for 6 months to 15 years were taken up for this study. The patients having dermographic urticaria of less than 6 months duration, pregnant female, patients below the age of 15 years and patients with any other systemic illness were excluded from the study. A thorough work-up comprising of a detailed history and physical examination was carried out in each patient. Pre-treatment laboratory evaluation in each patient included estimation of haemoglobin, total leucocyte count, differential leucocyte count, blood film morphology, erythrocyte sedimentation rate, fasting and post-prandial blood sugar levels, blood urea, serum creatinine, serum sodium and potassium levels, serum bilirubin, serum proteins, serum transaminases, serum alkaline phosphatase, urinalysis and stools examination for ova and cysts to look for any underlying occult infections, infestations, renal and /or liver disease and to monitor the side- effects, if any due to the subsequent treatment with systemic corticosteroids/ cyclophosphamide. The intensity of the dermographic response in each patient was graded with the help of an instrument called 'Dermograder' designed by Pasricha et al. The patients were divided into three groups. Group I patients were treated with cetirizine hydrochloride 10 mg per day orally, group II patients were given cetirizine as for group I, along with 2 mg of betamethasone per day orally, while group III patients received cetirizine as for group I along with cyclophosphamide 50 mg per day orally. The patients were evaluated every week during the therapy to assess the response to the treatment and also to monitor the side - effects. The response to the therapy was assessed by roughly grading the percent subjective improvement in itching and the occurrence of the wheals. The patients were also assessed by the dermograder to look for a change in the dermograde. After 4 weeks of therapy, all the drugs were stopped. A complete haemogram, fasting and post prandial blood sugar levels, liver and renal function tests, urinalysis and stools examination were carried out to look for abnormalities in any of these tests after the therapy. Thereafter, the patients were evaluated every month for 6 months or earlier to look for any recurrence.
| Results|| |
Out of 9 patients in group I, 6 patients had complete remission, while one patient each had 40%, 60% and 90% relief in their disease. All the patients in group II and group III had complete remission within the first week. Thus a total of 22 (88%) patients had complete relief while 3(12%) patients (group I) had partial response to the treatment Table 1. Three patients belonging to group II experienced a decrease of the dermograde from 4 to 3 after the third week of therapy, but in the remaining patients there was no change.
After stoppage of the treatment, the symptom-free period in group I was 24 hours in 2 patients, 48 hours in 1 patient, 25 days in 1 patient and 6 months in 2 patients. In group II, the symptom-free period was, 24 hours in 1 patient, 48 hours in 2 patients, 72 hours in 2 patients and 5 days in I patient. One patient had no recurrence even at the end of 6 months follow up. The symptom - free period in group III was 24 hours in 3 patients, 48 hours in 3 patients and 72 hours in 3 patients. The side effects in group I patients included drowsiness during the first week of the therapy only in 2 patients. In group II, all the patients complained of weight gain, 4 patients developed acne, 2 had cushingoid features, while 1 patient felt drowsiness during the initial 2-3 days. The weight gain in these patients was 1 kg in 1 patient, 2 kg in 3 patients,3 kg in 2 patients and 5 kg in one patient. In group III, only one patient experienced drowsiness during the initial 4-5 days of the treatment. None of the patients showed any change in the laboratory parameters during the period of the therapy.
| Discussion|| |
Antihistamines have been the mainstay of treatment ever since histamine was discovered to be the main mediator in urticaria. Although, these drugs are very effective in controlling the symptoms provided the dose of the antihistamine used is adequate, it is being increasingly realised that the antihistamines act only at the peripheral level and mask the symptoms. These drugs do not alter the course of the disease and have to be continued till the cause of the disease disappears spontaneously. That is why in chronic urticaria, the symptoms tend to reappear whenever the antihistamines are withdrawn. In a fixed dose schedule as used in this study, some patients may not obtain complete relief if the dose of the drug is less than the dose required to control the symptoms completely. Cetirizine is a fairly potent antihistamine which suppresses the urticaria effectively in most of the patients, and one dose a day is generally sufficient for 24 hours. Hence it was given to all the patients as the baseline treatment. With this dose alone (group) 3 patients could not obtain complete relief suggesting that some patients require a higher dose.
Systemic corticosteroids act at multiple levels, they suppress the formation of antibodies, they have a strong anti-inflammatory effect and in addition are known to decrease the production of histamine - releasing factors. In combination with cetirizine therefore, the control of urticaria is expected to be better and in group II therefore ( betamethasone 2 mg along with cetirizine hydrochloride 10 mg per day orally) all the patients had complete remission.
Cyclophosphamide belongs to the nitrogen mustard family of alkylating agents and is one of the most effective cytotoxic and immunosuppressive agents. The action of cyclophosphamide is not cell cycle specific and it can affect non-cycling cells also. It can cause differential cytotoxicity to various lymphoid cell populations, with selective suppression of the B cells. Hence, this drug is considered to be most effective in suppressing the humoral immunity. All the patients treated with cyclophosphamide 50 mg per day orally along with cetirizine hydrochloride 10 mg per day orally obtained complete relief, and they were symptomatically better controlled than the other groups. These results correspond to the beneficial effects reported with cyclosporine in chronic idiopathic urticaria.,,
Drowsiness was observed in our study in 4 (16%) of the patients in the three respective groups, but in all the patients this side effect was transitory and disappeared within the first few days. In group II in addition, all the patients had weight gain by 1-5 kg, 4 ( 57) % patients had acne, and 2 ( 29%) patients had cushingoid features. All these side effects are attributable to the systemic corticosteroids used in these patients. The weight gain however, was mild in a large proportion of the patients and returned to normal within 3 weeks after the corticosteroid was withdrawn. In group III in contrast, none of the patients had any side effects attributed to cyclophosphamide. This low dose of cyclophosphamide has been known to produce no side effects even when given for very long periods., The laboratory parameters also in all the patients remained within the normal range.
After stopping the treatment, 7 (77%) patients in group I, 5 (71%) patients in group II and all the (100%) patients in group III relapsed within 2-3 days indicating that the additional treatment with betamethasone or cyclophosphamide had made no significant difference in preventing a future relapse in these patients. This shows that a four week supplementation is not adequate to significantly alter the course of dermographic urticaria. In future studies therefore, it will be necessary to use either a larger dose and/or a longer duration of the treatment to significantly affect the pathogenic mechanisms responsible for this type of urticaria.
The study therefore, shows that cetirizine 10 mg per day used alone is sufficient to control dermographic urticaria in 67% of the patients. When combined with 2 mg betamethasone per day, all the patients experienced complete relief but weight gain, acne and cushingoid features were seen in 100%, 57%, and 29% of these patients. Combination with 50 mg cyclophosphamide per day, also produced complete relief but no side effects. Majority of the patients however relapsed within 3 days of withdrawing the drug suggesting that a four week supplementation with these immunosuppressive drugs is not adequate to significantly alter the course of the disease in dermographic urticaria.
| References|| |
Grattan CEH, Francis DM, Hide M, et al. Detection of circulating histamine releasing autoantibodies with functional properties of anti IgE in chronic urticaria. Clin Exp Allergy 1991;21:695-704.
Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Eng J Med 1993;328:1599-1604.
Fine RM. Autoimmune basis for chronic idiopathic urticaria. Int J Dermatol 1994;33:164-165.
Weiner MJ. Methotrexate in corticosteroid resistant urticaria. Ann Intern Med 1989;110:848.
Fradin MS, Ellis CN, Glodfarb MT, et al. Oral cyclosporin for severe chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1991;25:1065-1067.
Ellingsen AR, Thestrup-Pedersen K. Treatment of chronic idiopathic urticaria with topical steroids. Acta Derm Venereal (Stockh) 1996;76:43-44.
Pasricha JS, Dhillon IP. Grading the response in dermographic urticaria. Indian J Dermatol Venereal Leprol 1985;51:31-34.
Paradis L, Lavoie A, Brunet C, et al. Effects of systemic corticosteroids on cutaneous histamine secretion and histamine - releasing factor in patients with chronic idiopathic urticaria: Clin Exp Allergy 1996;26:815-820.
Hemendinger RA, Bloom SE. Selective mitomycin C and cyclophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo. Immunopharmacol 1996;35:71-82.
Barlow RJ, Blant AK, Greaves MW. Treatment of severe chronic urticaria with cyclosporin A. Eur J Dermatol 1993;3:273-275.
Toubi E, Blant A, Kessel A, et al. Low - does cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997;52:312-316.
Pasricha JS, Khaitan BK, Shanta - Roman R, et al. Dexamethasone cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995;34:875-878.
Pasricha JS, Khaitan BK. Curative treatment for pemphigus. Arch Dermatol 1996;132:1518-1519.
|This article has been cited by|
||Treatment of chronic urticaria
| ||Tončić, R.J., Lipozenčić, J., Marinović, B. |
| ||Acta Dermatovenerologica Croatica. 2009; 17(4): 305-322 |
||Therapeutic alternatives for chronic urticaria: An evidence-based review, part 2
| ||Morgan, M., Khan, D.A. |
| ||Annals of Allergy, Asthma and Immunology. 2008; 100(6): 517-526 |
||Determination of betamethasone in human plasma by liquid chromatography with tandem mass
| ||Qu, T.-T., Zhang, R., Wang, B.-J., Liu, X.-Y., Yuan, G.-Y., Guo, R.-C. |
| ||Yaoxue Xuebao. 2008; 43(4): 402-407 |